DNA BASED WOUND PANEL TESTING

Molecular Based Diagnostic Testing Facilitates Targeted Treatment Decisions
​
​AMT’s innovative wound panel helps achieve a better understanding of chronic and infected wounds by detecting pathogens and covert infections that can slow down the healing process. The test results can help clinicians make targeted treatment decisions to kick-start the healing process and enhance patient outcomes.

Our DNA based wound panel testing keeps facilities ahead of the curve with upcoming surveys enforcing CMS final rule 483.80 that requires facilities to have:

• A system for preventing, identifying, reporting, investigating, and controlling infections
• A system of surveillance designed to identify possible communicable disease or infections before they can spread to other persons in the facility
• An antibiotic stewardship program that includes antibiotic use protocols and a system to monitor antibiotic use

Our program addresses the above and reduces the risk of future survey infractions by:

• Providing results within 72 hours after the lab receives a sample
• Giving clinicians the evidence to support their decisions
• Reduced broad spectrum antibiotic use
• Assisting with antibiotic stewardship in the facility
• Test results provide documentation required to help satisfy the PDPM compliance needs

Solution For Biofilm Management

Bacteria that form biofilms can accumulate in the wound bed to fight and prevent healing. Now we don’t have to wait for a routine culture that will only provide part of the story. The latest technology in DNA testing gives us the tools we need to find the pathogens responsible for possible infection or a chronic condition.

​For wounds that are showing signs and symptoms of increased bioburden or have stalled in the healing process, the DNA-based wound panel test from AMT and NextGen can provide the data needed to treat the wound effectively and kick-start the healing process.

Wound Biofilm: Current Perspectives and Strategies on Biofilm Disruption and Treatments”, published in WOUNDS June 2017 recommends a  step-down and step-up approach to biofilm management.

Precision Wound Management provides the recommended DNA identification of microorganisms, biofilm disruption technology and personalized topical treatment options.
​

“Wound Biofilm: Current Perspectives and Strategies on Biofilm Disruption and Treatments”. Figure 3 page 12, June, 2017 issue of WOUNDS. Used with permission.

Pathogens Tested

• Acinetobacter baumannii
• Anaerococcus spp.
• Bacteroides fragilis
• Enterococcus faecalis
• Enterococcus faecium
• Escherichia coli
• Klebsiella pneumoniae
• ​Proteus mirabilis
• Pseudomonas aeruginosa
• Serratia marcescens​
• Staphylococcus aureus
• Staphylococcus epidermidis
• ​Streptococcus agalactiae

​

REQUEST CONSULTATION 

Learn how our DNA based wound panel can help your facility improve outcomes and support  compliance requirements. Request a complimentary consultation from our Clinical Specialists.

ARE YOU READY TO MAKE TARGETED TREATMENT DECISIONS?

CONTACT OUR TEAM